Larry Solow: Great, thanks. Good morning, everybody. Just a couple of follow-ups. Most of my questions have been answered. But on PYLARIFY, Paul, you mentioned year-over-year growth coming from new and existing accounts sequentially. Obviously, it’s a little slower growth, too, but just in terms of you said mostly out of existing accounts. Can you just give us an update on sort of where you stand and your reach to — there’s still a lot of potentially new accounts that you haven’t reached yet. Can you kind of give us some thoughts around that? And also, you mentioned PMF facility expansion. Can you give us just an update on the sort of scorecard there?
Paul Blanchfield: Yeah, sure. Thanks, Larry. Appreciate the question. So we made a distinction, year-over-year, if we compare the third quarter of ’23 to the third quarter of ’22, growth was driven by existing accounts as well as new accounts and additional PMF activations. If we speak sequentially, the vast majority of growth was driven by existing accounts. In that were over 50 PMFs, whereabout 54 PMFs currently activated. We do continue to activate new PMFs, specifically in geographic areas where additional dose time flexibility is important. But the driver has been and continues to be, if we look kind of quarter-over-quarter and certainly into the future, will be the activation of existing accounts where we already have imaging centers, whether they be freestanding or hospital or government facilities that have access to and are regularly offering PYLARIFY and where it is certainly being requested by name.
The real work that we’ve been on for the last year is to continue to activate the referring community. That would be urology, that would be medical oncology, radiation oncology, for them to understand who the target patient is, the frequency in which those patients could be scanned and we still see significant room for growth in that space. The vast majority of accounts have adopted some sort of PSMA PET imaging, a market that’s annualizing approximately $1.3 billion, meaning there’s not too many accounts out there that are not already adopting. There may be some small mobile facilities where either due to geographics or just timing of offering we have to be able to add. But I would call that effectively de minimis going forward. Really, the growth in this market is going to continue to be the activation of referring physicians, ensuring that they understand the breadth of our label and the significant potential that PSMA PET imaging can make to clinical practice as evidenced by the change in intended management data, where this is not just a diagnostic, this can truly inform patient management.
And we think that clinical benefit plus our broader commercial benefits will continue to support our growth going forward.
Operator: Thank you. And for your next question, it comes from the line of Yuan Zhi from B. Riley. Yuan, your line is open. Please ask your question.
Yuan Zhi: Good morning. Thank you for taking our questions and congrats on the quarter. Can you please clarify the total cost of a PSMA PET scan on average? I mean the cost of the agents and the procedure in either hospital setting or outpatient setting? Thank you.
Paul Blanchfield: Yuan, first of all, thank you for the question. I may ask a follow-up question to you, if you will. But the total cost of the procedure is certainly going to vary. So if you think about the cost of procedure to either a hospital or a freestanding imaging center, there’s naturally a cost of the tracer, which would effectively be PYLARIFY for the vast majority of PSMA PET scans, and then there are certainly three other commercial agents and two other academic agents available. Commercially, the agents are priced relatively close together. And so when we look at what that is, that’s a fairly consistent cost across the marketplace. Now to estimate the cost of the procedure, there’s a fixed cost that’s going to be associated with the PET/CT scanner, which is usually an investment in the millions of dollars, but then will last many years.
